Patent for Cancer Treatment Using Fusion Protein Disclosed

Strategic Insights -

A breakthrough in cancer treatment has been patented, utilizing a fusion protein that targets angiogenesis, a crucial process in cancer growth. The patent, filed on July 25, 2012, and published on March 24, 2015, is assigned to Samsung Electronics Co., Ltd. and details a novel approach to treating cancer using a fusion protein.

Key Takeaways:

  • The patent describes a fusion protein consisting of two components: a polypeptide that specifically binds to Annexin A1 and a polypeptide that induces a cytotoxic activity of a cytotoxic lymphocyte.
  • The fusion protein is designed to target angiogenesis, a process essential for cancer cell differentiation and growth.
  • There are currently 16 commercially available antibodies for treatment, and about 7000 or more are under development by around 300 or more companies worldwide.
  • The pharmaceutical market for antibody products is continuously growing.
  • The inventive pharmaceutical compositions are intended to treat or prevent cancer using the fusion protein.
  • Angiogenesis is a low-efficiency target for inhibition, and no single therapeutic agent has been widely available.
  • Annexin A1, a protein involved in bone structural formation and various biological phenomena, is used as a marker for cancer.

Statistics:

  • 16 antibodies for treatment are commercially available.
  • 7000 or more antibodies are under development by around 300 or more companies worldwide.
  • The pharmaceutical market for antibody products is growing.
  • Angiogenesis is a critical process in cancer growth, and its inhibition is a significant challenge.
  • Annexin A1 is found in various living organisms, including humans, and is involved in bone formation and other biological phenomena.

Sources:

  • Lee, Jae-il. Pharmaceutical Composition for Preventing Or Treating Cancer. U.S. Patent Number 8987425, filed July 25, 2012, and published online on March 24, 2015. Patent URL: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8987425.PN.&OS=PN/8987425RS=PN/8987425